CoChat
Sign Up
Cited by 900Multiple Myeloma Research and TreatmentsBone health and treatmentsMultiple Sclerosis Research Studies

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Open access
Dimopoulos, M.A., Moreau, P., Terpos, E., Mateos, M.V., Zweegman, S., Cook, G., Delforge, M., Hájek, R. +9 more·2021·Annals of Oncology
DOI 10.1016/j.annonc.2020.11.014PMC PMC7861652
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.11.014

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 66

  1. [1]1. Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project. Blood Cancer J. 2018;8:123.
  2. [3]3. Caers J, Garderet L, Kortüm KM, et al. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica . 2018;103:1772-1784.
  3. [4]4. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol . 2016;17:e328-e346.
  4. [5]5. Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv . 2020;4:2163-2171.
  5. [6]6. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood . 2018;132:2456-2464.
  6. [7]7. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol . 2017;3:28-35.
  7. [8]8. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol . 2017;18:e206-e217.
  8. [9]9. Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk . 2020;20:e30-e37.
  9. [10]10. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol . 2014;15:e538-e548.
  10. [11]11. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood . 2015;125:3069-3075.
  11. [13]13. Mateos MV, Hernández MT, Giraldo P , et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol . 2016;17:1127-1136.
  12. [14]14. Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol . 2020;38:1126-1137.
  13. [15]15. Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia . 2020;34:1840-1852.
  14. [17]17. Attal M, Lauwers-Cances V, Hulin C, et al. IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med . 2017;376:1311-1320.
  15. [18]18. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stemcell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol . 2020;7:e456-e468.
  16. [19]19. Sonneveld P , Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol . 2013;31:3279-3287.
  17. [20]20. Moreau P , Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood . 2016;127:2569-2574.
  18. [21]21. Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia . 2015;29:1721-1729.
  19. [23]23. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood . 2020;136:936-945.
  20. [24]24. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol . 2020;38:1928-1937.
  21. [26]26. Moreau P , Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet . 2019;394:29-38.
  22. [29]29. Blanes M, Lahuerta JJ, González JD, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant . 2013;19:69-74.
  23. [30]30. Blanes M, Lorenzo JI, Ribas P , et al. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Ann Hematol . 2019;98:2013-2015.
  24. [34]34. Giralt S, Costa LJ, Maloney D, et al. Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant . 2020;26:798-804.
  25. [37]37. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol . 2017;35:3279-3289.
  26. [38]38. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol . 2019;20:57-73.
  27. [40]40. Dimopoulos MA, Gay F, Schjesvold F , et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet . 2019;393:253-264.
  28. [41]41. San Miguel JF , Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med . 2008;359:906-917.
  29. [43]43. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet . 2017;389:519-527.
  30. [45]45. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med . 2018;378:518-528.
  31. [46]46. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet . 2020;395:132-141.
  32. [48]48. Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol . 2006;132:205-212.
  33. [49]49. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med . 2012;366:1759-1769.
  34. [50]50. Dimopoulos M, Špi č ka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple lyeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol . 2020;38:4030-4041.
  35. [51]51. Cook G, Ashcroft AJ, Cairns DA, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol . 2016;3:e340-e351.
  36. [53]53. Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant . 2015;21: 2039-2051.
  37. [54]54. Miller KC, Gertz MA, Buadi FK, et al. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant . 2019;54:2039-2050.
  38. [55]55. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med . 2015;372:142-152.
  39. [57]57. Moreau P , Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med . 2016;374:1621-1634.
  40. [59]59. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol . 2018;36:728-734.
  41. [60]60. Dimopoulos M, Weisel K, Lonial S, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival results from the phase 3 ELOQUENT-2 trial. Presented at: 17th International Myeloma Workshop; September 12-15, 2019: Boston, MA. Abstract OAB-021.
  42. [61]61. Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica . 2010;95:1738-1744.
  43. [62]62. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol . 2017;18:1327-1337.
  44. [63]63. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med . 2016;375:754-766.
  45. [67]67. Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, et al. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood . 2018;131:464-467.
  46. [68]68. Nooka AK, Joseph NS, Kaufman JL, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer . 2019;125:2991-3000.
  47. [69]69. Harrison S, Cavo M, De La Rubia J, et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood . 2019;134:142.
  48. [71]71. Dimopoulos MA, Richardson PG, Moreau P , et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol . 2015;12:42-54.
  49. [72]72. Gandhi UH, Cornell RF , Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia . 2019;33:2266-2275.
  50. [73]73. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med . 2018;379:1811-1822.
  51. [74]74. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet . 2019;394:2096-2107.
  52. [75]75. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood . 2017;130:974-981.
  53. [76]76. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med . 2019;381:727-738.
  54. [77]77. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol . 2020;21:207-221.
  55. [78]78. Richardson PG, Bringhen S, Voorhees P , et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol . 2020;7:e395-e407.
  56. [79]79. Raje N, Berdeja J, Lin Y , et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med . 2019;380:1726-1737.
  57. [80]80. Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia . 2013;27:780-791.
  58. [81]81. Gavriatopoulou M, Musto P , Caers J, et al. European Myeloma Network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia . 2018;32:1883-1898.
  59. [82]82. Musto P , Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia . 2014;28:222-225.
  60. [83]83. Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myélome. J Clin Oncol . 2016;34:2125-2132.
  61. [85]85. Dhakal B, Patel S, Girnius S, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia . 2020;34:3338-3347.
  62. [86]86. Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol . 2002;3:255-259.
  63. [87]87. Paiva B, Chandia M, Vidriales MB, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood . 2014;124:1300-1303.
  64. [88]88. Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol . 2015;33:657-664.
  65. [89]89. Tsang RW, Campbell BA, Goda JS, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys . 2018;101:794-808.
  66. [90]90. Dykewicz CA, Centers for Disease Control and Prevention (U.S.); Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis . 2001;33:139-144. (Adapted from: Gross PA, Barrett TL, Dellinger EP , et al. Purpose of quality standards for infectious diseases. Clin Infect Dis . 1994;18:421.)

Cited by

Sorted by citations

Authors
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., Goldschmidt, H., Facon, T., Einsele, H., Boccadoro, M., San-Miguel, J., Sonneveld, P., & Mey, U.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Instituto de Investigación Biomédica de Salamanca (ES)
  • Amsterdam University Medical Centers (NL)
  • University of Leeds (GB)
  • Universitair Ziekenhuis Leuven (BE)
  • University Hospital Ostrava (CZ)
  • Oslo University Hospital (NO)
  • University of Bologna (IT)
  • University Hospital Heidelberg (DE)
  • Hôpital Claude Huriez (FR)
  • Universitätsklinikum Würzburg (DE)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Erasmus MC (NL)
  • Kantonsspital Graubünden (CH)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-03
Volume
32
Issue
3
Pages
309-322
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2020.11.014
PMC
PMC7861652
OpenAlex
W3127065235
Cited by
900
References
11
Citations by year
2026: 103 · 2025: 192 · 2024: 200 · 2023: 177 · 2022: 150 · 2021: 74 · 2013: 1
FWCI
98.18
Type
journal article
Language
en
Update notices
erratum (2022-01-01)
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Lirias (submittedVersion, cc-by-nc-nd)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Sanofi
  • Celgene
  • Johns Hopkins University
  • Adaptive Biotechnologies
  • Incyte
  • Genesis Pharma
  • European Society for Medical Oncology
  • PharmaMar
  • Chugai Pharmaceutical
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
multiple myeloma, plasma cell neoplasms, diagnosis, treatment, follow-up, survival, incidence
MeSH terms
Follow-Up Studies, Humans, Multiple Myeloma, Societies, Medical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review